boston scientific

Deutsche Bank is out with its report today on Boston Scientific (NYSE: BSX), maintaining Hold. In a note to clients, Deutsche Bank writes, "Medtronic's results did not change our view on BSX shares. MDT's results underscore the ICD market is challenged (more than expected) and when combined with...

Goldman Sachs has upgraded Boston Scientific (NYSE: BSX) from Sell to Neutral and has raised the price target from $6.50 to $7.

Medtronic (NYSE: MDT) is scheduled to report fiscal fourth-quarter 2011 results before the markets open tomorrow, May 24. Analysts expect the medical device maker to announce that per-share earnings inched up 3 cents from a year ago to $0.93. That consensus estimate is unchanged from 60 days ago....

J.P. Morgan reports that Boston Scientific (NYSE: BSX) reported 1Q results Wednesday night, with sales of $1.925B (-1.8% reported, -0.7% organic) coming in $30M ahead of the Street “and $18M above our own forecast, due in large part to currency.” “The big story in the quarter, though, is down the...

According to Deutsche Bank, Boston Scientific (NYSE: BSX) is facing another Guidant CRM impairment charge. Deutsche Bank said that recovery is still some way off. “Boston Scientific closed the Guidant acquisition exactly 5 years ago today for an aggregate purchase price of $28.4B, selling the...

Jefferies is out with its report today on Boston Scientific (NYSE: BSX), maintaining Hold. In a note to clients, Jefferies writes, "BSX is early in a multi-year reshuffle, complete with a lot of near-term disruption and plenty of risk around whether the promise of faster revenue growth in the out...

Duetsche Bank has lowered the price target on Boston Scientific (NYSE: BSX) from $8 to $7.40 and maintains its Hold rating.

Piper Jaffray is out with its report on Boston Scientific (NYSE: BSX), previewing Q4 10 earnings before they are announced this evening. In a note to clients, Piper Jaffray writes, "Barring a major miss relative to expectations, we think Q4 results are largely academic with the focus largely on the...

Wells Fargo makes the following EPS revisions: FY10 FY11 Old New Old New Phillips-Van Heusen(NYSE: PVH) $3.80 $3.95 $4.68 $4.90 Vera Bradley Inc.(NASDAQ: VRA) $1.03 $1.07 $1.07 $1.15 Boston Scientific (NYSE: BSX...

Collins Stewart has published a research report on the Medical Devices and Hospital Supplies sector and reports on its top picks for the group. In the report, Collins Stewart writes "We believe that FDA approval of Protecta ICD and Revo could provide MDT with an incremental $50 million (1% market...

Jefferies & Co. has published a research report for Boston Scientific Corporation (NYSE: BSX) with new coverage initiated. In the report, Jefferies writes "We are initiating coverage on Boston Scientific (BSX) with a Hold rating. Since its acquisition of Guidant in 2006, Boston has weathered a...

Upgrades: Estacio Participacoes SA (SAO: ESTC3) upgraded from Equal to Overweight, price target remains at $25, 2010 EPS raised to $1.15 (from $1.12), 2011 raised to $1.32 (from $1.15). Downgrades: Adobe Systems (NASDAQ: ADBE) downgraded to Equal from Overweight, price target remains at $42....

Initiation coverage from Deutsche Bank for September 10 is as follows: St. Jude Medical (NYSE: STJ) Initiate with Hold Rating and $39 price target Boston Scientific (NYSE: BSX) Initiate with Hold rating and $6.30 price target. Zimmer Holdings (NYSE: ZMH) Initiate with Hold rating and $53 price...

St. Jude Medical (NYSE: STJ) Initiate with Hold Rating and $39 price target Boston Scientific (NYSE: BSX) Initiate with Hold rating and $6.30 price target. Zimmer Holdings (NYSE: ZMH) Initiate with Hold rating and $53 price target CareFusion Corporation (NYSE: CFN) Initiate with Hold rating and $23...

Boston Scientific Corporation (NYSE: BSX) has reported solid 2Q results, with sales at $1.928B, coming in $17M above Street consensus. EPS showed at $0.12, one penny below J.P. Morgan's estimate, thanks to strong gross margin and lower operating expenses. JPM projects EPS of $0.60 for the full...